Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
NCT06105554
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study is unique because it combines two different therapies to see if they work better together than separately. Here are some key points about the study:
- The study focuses on patients who have already received treatment but still have signs of the disease.
- It tests a combination of a new drug and an existing treatment to see if this combination can improve patient outcomes.
- Patients will be monitored closely to track their progress and any side effects from the treatment.
- The goal is to find a more effective way to manage the disease and improve the quality of life for patients.
- This study is being conducted at multiple centers, allowing for a diverse group of participants.
Third Opinion AI Generated Synopsis
Trial Summary
Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
